(PCRX) Pacira BioSciences, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PCRX) Pacira BioSciences, Inc. Complete Analysis Pack
Pacira BioSciences: A Clear Blueprint of Its Biotech Business Model
Unlock the full strategic blueprint behind Pacira BioSciences, Inc.'s business model. This concise Business Model Canvas reveals how the company creates value, serves key customers, and supports growth in a competitive biotech market. Ideal for investors, analysts, and strategists seeking actionable insight—get the full version today.
Partnerships
U.S. contract manufacturers
Pacira BioSciences, Inc. uses U.S. contract manufacturers for sterile injectable and device output, including commercial supply for EXPAREL, ZILRETTA, and iovera. This setup lets Pacira avoid owning every production step and helps protect supply while keeping capital tied up in manufacturing assets lower.
Group purchasing organizations
Pacira BioSciences, Inc. uses group purchasing organizations to reach hospital buying networks, and the top GPOs cover about 96% of U.S. acute-care hospitals. These contracts matter for formulary placement and purchasing terms, which helps Pacira win adoption inside large health systems.
Integrated delivery networks
Pacira BioSciences, Inc. works with integrated delivery networks to standardize product use across multiple facilities, which matters for hospital-based procedures and formulary adoption. In FY2025, this channel stayed important because system-level wins can scale institutional uptake of Pacira BioSciences, Inc. pain-management products faster than single-hospital deals.
Clinical investigators
Clinical investigators and study sites help Pacira BioSciences, Inc. run clinical development, generate new data, and support post-market studies, which is key for product education and specialist adoption. Their role matters because physician-led evidence can move adoption faster than promotion alone, especially in procedure-based care.
- Support trials and real-world evidence
- Build trust with specialist physicians
- Strengthen post-market product education
Distributors and wholesalers
Distributors and wholesalers are key for Pacira BioSciences, Inc. because they move physician-administered and hospital-based products through U.S. healthcare channels, keeping inventory in stock and orders filled fast. For products sold into surgery centers and hospitals, that access path matters because missed availability can delay care.
- Support U.S. channel reach
- Keep inventory available
- Speed order fulfillment
- Fit hospital-based demand
Pacira’s FY2025 Partnerships Power Access, Supply, and Adoption
Pacira BioSciences, Inc.'s key partnerships in FY2025 centered on contract manufacturers, top group purchasing organizations, and integrated delivery networks, which together support supply, access, and formulary wins for EXPAREL, ZILRETTA, and iovera. Clinical investigators and distributors also matter because they help generate evidence, reach hospitals and surgery centers, and keep inventory moving.
| Partner | FY2025 role | Why it matters |
|---|---|---|
| GPOs | Top 3 cover ~96% U.S. acute-care hospitals | Access and pricing |
| CMOs | Make sterile supply | Capacity and continuity |
| IDNs | Standardize use | Scale adoption |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Pacira BioSciences, mapping its 9 blocks, key customers, and growth drivers for investors and strategists.
Customizable Excel Spreadsheet
Quickly maps Pacira BioSciences’ pain-relief business model in a clear, editable format.
Reference Sources
Lists credible sources behind Pacira BioSciences data to verify assumptions fast and support confident decisions.
Activities
Sterile product manufacturing
Pacira BioSciences, Inc.'s sterile manufacturing keeps its two flagship U.S. pain brands, EXPAREL and ZILRETTA, moving through quality control, batch release, and supply planning. Reliable output matters because hospital and physician channels depend on on-time, compliant supply; even one delayed batch can push out revenue timing and disrupt patient care.
Sales and clinician education
In fiscal 2025, Pacira BioSciences, Inc. used its commercial and medical education teams to train surgeons, anesthesiologists, and other providers on EXPAREL and other procedure-based therapies, which supports adoption and correct use. This matters in branded procedural care, where site-level training can affect thousands of surgeries and repeat purchasing decisions.
Clinical development
Pacira BioSciences runs clinical development to expand approved uses, generate evidence, and support lifecycle management for its non-opioid pain portfolio. In 2024, Pacira reported net product sales of $627.9 million, and clinical data from studies like these help back both FDA strategy and commercial differentiation in a market where Exparel remains the core revenue driver.
Regulatory and quality compliance
Pacira BioSciences must keep FDA compliance tight across drugs and devices, including pharmacovigilance, labeling, and cGMP controls. In 2024, the Company reported $717.8 million in net sales, so execution on regulatory quality is not back-office work; it is a core operating risk that protects product access and revenue.
- FDA compliance across drugs and devices
- Pharmacovigilance and labeling control
- Manufacturing standards and inspections
MVL platform development
Pacira BioSciences continues to develop its multivesicular liposome platform to load therapeutic compounds and keep their structure intact. The platform supports product pipeline growth and underpins approved brands such as EXPAREL, a key driver of 2025 revenue of $618.5 million in Pacira BioSciences’ latest reported full year.
- Encapsulates drugs in multivesicular liposomes
- Protects molecular structure and release profile
- Supports future product innovation
Pacira’s manufacturing and compliance drive $618.5M in 2025 sales
Pacira BioSciences, Inc.’s key activities are sterile manufacturing, FDA quality control, and clinical development for EXPAREL, ZILRETTA, and its multivesicular liposome platform. In fiscal 2025, net product sales were $618.5 million, so reliable batch release and regulatory compliance directly support revenue and access.
| Key activity | 2025 data |
|---|---|
| Net product sales | $618.5 million |
Full Version Awaits
Business Model Canvas
This Pacira BioSciences, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a live section of the final file, formatted and structured the same way. Once your order is complete, you’ll get full access to this same ready-to-use document with no surprises.
Resources
EXPAREL franchise
EXPAREL is Pacira BioSciences, Inc.'s flagship liposomal bupivacaine product and the core commercial asset in postsurgical pain care. It supports the company’s non-opioid analgesia position with 72-hour local pain control, and in 2025 it remained the main revenue driver for Pacira BioSciences, Inc.
ZILRETTA franchise
ZILRETTA, Pacira BioSciences, Inc.'s extended-release triamcinolone acetonide injection for knee osteoarthritis pain, gives the Company a second branded therapeutic platform alongside EXPAREL. In 2024, it generated roughly $160 million in net product sales, helping diversify Pacira BioSciences, Inc.'s pain portfolio beyond procedural care.
iovera system
Pacira BioSciences, Inc.’s iovera system is a distinct handheld cryoanalgesia device that uses controlled cold to target peripheral nerves and block pain at the source. It strengthens Pacira BioSciences, Inc.’s non-opioid toolkit alongside EXPAREL, giving the Company a commercial asset in a market where opioid-sparing care remains a priority.
MVL drug delivery technology
Pacira BioSciences, Inc.'s multivesicular liposome platform is a core IP asset that drives its sustained-release drug delivery model and supports product development. In fiscal 2025, the company reported $0.7 billion in net revenue, with Exparel still the main commercial proof point for this technology.
- Core IP: multivesicular liposome platform
- Differentiated sustained-release delivery
- Backs product design and pipeline work
- 2025 net revenue: about $0.7 billion
Commercial and medical affairs teams
Pacira BioSciences, Inc.'s commercial and medical affairs teams are core human resources: sales, market access, and medical staff drive product education, reimbursement talks, and hospital adoption in specialty care. In FY2025, that support matters most where access and protocol buy-in can shape demand fast.
- Sales drives institutional adoption
- Market access supports reimbursement
- Medical teams build clinician trust
These teams help convert clinical value into paid use, which is critical in high-touch healthcare markets.
Pacira's Core Assets Drive ~$700M in 2025 Revenue
Pacira BioSciences, Inc.'s key resources are EXPAREL, ZILRETTA, and the iovera system, plus the multivesicular liposome platform that underpins its long-acting drug delivery model. In fiscal 2025, Pacira BioSciences, Inc. reported about $700 million in net revenue, with EXPAREL still the main commercial engine and ZILRETTA adding about $160 million in 2024 net product sales.
| Resource | 2025/2024 Data |
|---|---|
| EXPAREL | Main revenue driver in 2025 |
| ZILRETTA | ~$160M net sales in 2024 |
| Company revenue | ~$700M net revenue in 2025 |
Value Propositions
Non-opioid pain management
Pacira BioSciences' EXPAREL gives up to 72 hours of postsurgical pain control, helping reduce opioid use in surgical and orthopedic care. In 2024, Pacira reported about $595 million in net sales, showing its non-opioid pain positioning is a core commercial driver.
Long-acting local analgesia
XPAREL is Pacira BioSciences, Inc.'s extended-release liposomal bupivacaine, designed to deliver local analgesia for up to 72 hours after surgery. Pacira reported 2024 net product sales of $625.1 million, and XPAREL remains the core product where sustained pain control matters most.
Extended-release knee OA relief
Pacira BioSciences, Inc.'s ZILRETTA is a 32 mg extended-release triamcinolone injection for knee osteoarthritis pain, designed to deliver steroid control for up to 12 weeks from one shot. It gives clinicians a branded injectable option in a U.S. OA market that affects about 32.5 million adults.
Targeted cryoanalgesia
Targeted cryoanalgesia gives Pacira BioSciences, Inc. a precise, non-opioid way to treat pain by cooling targeted nerves with a handheld device, which fits procedure-based workflows where speed and control matter. This matters in a market still shaped by opioid-sparing demand, with Pacira reporting 2024 net sales above $680 million.
- Precisely cools targeted nerves
- Handheld, non-opioid pain option
- Fits procedure-based care workflows
Preserved molecular delivery
Pacira BioSciences’ MVL technology encapsulates compounds while preserving their molecular structure, which helps create distinct release and delivery behavior. That supports the Company Name’s formulation strategy across new products, including its portfolio built around non-opioid pain care; in 2025, Pacira reported about $700 million in net product sales.
- Preserves molecular structure
- Creates differentiated delivery
- Supports new product formulation
Pacira’s Non-Opioid Pain Model Delivers $700M in 2025 Sales
Pacira BioSciences, Inc. sells non-opioid pain care built around EXPAREL, ZILRETTA, and targeted cryoanalgesia, giving surgeons and clinicians longer pain control with less opioid use. In 2025, Pacira reported about $700 million in net product sales, showing the model’s commercial pull.
| Value proposition | 2025 data |
|---|---|
| Non-opioid pain control | ~$700M net product sales |
Customer Relationships
Field-based account management
Pacira BioSciences keeps direct field teams in hospitals and provider groups to handle contracting, payer access, and product adoption. This is standard for specialty healthcare products, where local support can speed formulary wins and help sustain use across surgical and acute-care sites.
Clinical education support
Pacira BioSciences trains physicians and care teams on indications, administration, and expected outcomes, so users can apply both its drugs and device-based therapies correctly. This clinical education support helps reduce misuse risk and supports adoption across the company’s non-opioid portfolio.
Medical affairs engagement
Pacira BioSciences uses medical affairs teams to answer scientific and clinical questions, so the relationship is built on evidence, label guidance, and appropriate use. In its latest annual filings, Pacira reported about $670 million in annual revenue, and that scale helps support trust with specialists and hospitals that want clear data before adopting EXPAREL.
Reimbursement assistance
Reimbursement assistance helps physicians and hospitals verify benefits, secure prior authorization, and reduce payment delays for Pacira BioSciences, Inc. physician-administered products like EXPAREL. This support can speed adoption inside health systems, where coverage rules often shape whether a therapy is used.
For site-of-care decisions, faster access matters: even a few days of payer delay can slow surgical scheduling and limit repeat use. Pacira BioSciences, Inc. also uses this channel to lower friction for providers managing complex medical claims.
- Verifies benefits and coverage
- Supports prior authorization
- Reduces payment friction
- Helps health-system adoption
Post-sale device support
Post-sale device support keeps Pacira BioSciences, Inc. products in use by giving clinical teams onboarding, training, and day-to-day operating guidance. This matters because strong service helps sustain real-world utilization in hospitals and ambulatory surgery settings.
- Onboard users fast
- Train staff on workflow
- Support ongoing device use
- Protect clinical adoption
Pacira’s Clinical Support Network Powers $670M in Revenue
Pacira BioSciences, Inc. keeps hospital and physician ties tight through field teams, medical affairs, and reimbursement help. That matters in specialty care: in its latest annual filings, Pacira BioSciences, Inc. reported about $670 million in annual revenue, showing the scale behind its clinical and payer support.
| Channel | Role | Data point |
|---|---|---|
| Field and medical teams | Train, support, answer clinical questions | ~$670 million revenue |
Channels
Direct hospital sales
Pacira BioSciences, Inc. sells directly to hospitals through its commercial team, and this channel is the main route for EXPAREL in inpatient and surgical care. It matters because hospital-administered, procedure-linked use drives most of Pacira BioSciences, Inc.'s pain-management demand, so sales reps focus on surgeons, anesthesiology teams, and pharmacy buyers.
Ambulatory surgery centers
Ambulatory surgery centers are a key outpatient channel, with about 6,300 Medicare-certified sites in the U.S. Pacira BioSciences, Inc.’s non-opioid pain products fit these settings well because ASCs need fast recovery, fewer opioid side effects, and same-day discharge after surgery.
Physician office channel
Physician office channel is important for Pacira BioSciences, Inc. because orthopedists and pain physicians can purchase or administer products directly in office-based settings. It matters most for ZILRETTA and iovera, supporting direct clinician access and faster use in routine care.
GPO and IDN contracting
Pacira BioSciences, Inc. uses GPO and IDN contracting to win formulary access across large care systems, which drives standard purchasing and scale in the U.S. market. Industry data show GPOs influence about 96% of U.S. hospital purchases, so these channels matter for repeat volume and broader adoption.
- Drives formulary access
- Supports standard purchasing
- Scales across IDNs and hospitals
Medical education events
Medical education events are a high-trust channel for Pacira BioSciences, Inc.; conferences and scientific meetings put EXPAREL and other products in front of surgeons, anesthesiologists, and pain specialists, and the 2025 ASRA annual meeting drew more than 2,000 clinicians, a useful scale for peer-to-peer reach. This channel supports clinical evidence, reinforces positioning, and helps convert data into prescriber confidence.
- Reaches high-value HCPs
- Builds clinical credibility
- Supports evidence-driven adoption
Pacira’s Hospital-First Sales Model Drives EXPAREL Reach
Pacira BioSciences, Inc. sells mainly through direct hospital teams, with EXPAREL tied to inpatient and surgical use, while ASCs, physician offices, and GPO/IDN contracts broaden reach across care settings. Medical meetings also matter: the 2025 ASRA annual meeting drew more than 2,000 clinicians, helping convert evidence into use.
| Channel | Key data |
|---|---|
| Hospitals | Primary route for EXPAREL |
| ASCs | About 6,300 Medicare-certified U.S. sites |
| GPOs | Influence about 96% of U.S. hospital purchases |
Customer Segments
Hospitals
Hospitals are Pacira BioSciences, Inc.'s core buyers and users for EXPAREL and other pain-management products, especially for surgery and inpatient care. In FY2025, this segment stayed central to commercial execution because hospitals keep pushing opioid-sparing options that can support recovery, cut opioid use, and fit bundled care economics.
Ambulatory surgery centers
Ambulatory surgery centers are a high-volume outpatient channel, with more than 6,200 Medicare-certified sites in the U.S. They want therapies that speed recovery and cut opioid use, so Pacira BioSciences, Inc. products like EXPAREL fit well in same-day procedures where fast turnover and pain control drive results.
Orthopedic surgeons
Orthopedic surgeons are Pacira BioSciences, Inc.'s core prescribers and users, especially in knee surgery and postsurgical pain care. In 2025, that matters because U.S. knee arthroplasty volumes stayed above 800,000 procedures, so surgeon adoption directly drives product use, procedure mix, and repeat hospital system demand.
Anesthesiologists and pain specialists
Anesthesiologists and pain specialists manage perioperative and chronic pain pathways, and they are key users of EXPAREL, which is FDA-approved for up to 72 hours of postsurgical pain control. They also use iovera and often shape hospital protocols, so their adoption can affect standard of care across surgery centers and health systems.
- Drive perioperative pain protocols
- Use EXPAREL and iovera
- Influence hospital formulary decisions
Patients with postsurgical or OA pain
Patients with postsurgical pain and adults with knee osteoarthritis pain are Pacira BioSciences, Inc.'s end users. Knee osteoarthritis affects about 32.5 million U.S. adults, and Pacira designs non-opioid therapies like EXPAREL and ZILRETTA around these pain needs.
- End users: surgery and OA pain patients
- Large pool: 32.5 million OA adults
- Focus: non-opioid pain control
Pacira’s Core Buyers Fuel Opioid-Sparing Surgery Growth
Pacira BioSciences, Inc. mainly sells to hospitals, ambulatory surgery centers, and orthopedic surgeons that choose non-opioid pain care for surgery. In FY2025, these buyers mattered most because U.S. knee arthroplasty stayed above 800,000 cases and more than 6,200 Medicare-certified ASCs kept pushing faster recovery and opioid-sparing care.
| Customer segment | Why it matters |
|---|---|
| Hospitals | Formulary and inpatient use |
| ASCs | High-volume outpatient surgery |
| Orthopedic surgeons | Key prescribers in knee care |
Cost Structure
R&D and clinical studies
Pacira BioSciences, Inc. spent heavily on product development, trial work, and evidence generation, with R&D and clinical study costs at about $47 million in fiscal 2025. That spend supports label expansion and lifecycle management for its core biopharma and medtech portfolio, where clinical data is a direct driver of growth and market access.
Manufacturing and supply chain
Pacira BioSciences, Inc. bears heavy cost in sterile injectables and device production, where materials, testing, packaging, and logistics all sit inside COGS; in 2025, its net product sales were driven by these high-touch supply needs. Supply reliability stays a major cost driver, because any shortage or delay pushes up buffer stock and rush-freight spend.
Sales and marketing
Pacira BioSciences, Inc. keeps sales and marketing high because its commercial model depends on field reps, surgeon education, and promo work to drive adoption in physician-led specialty care. In 2025, that spend supported EXPAREL and iovera access across hospitals, where each account can take weeks of training and contract work.
General and administrative
General and administrative costs cover Pacira BioSciences, Inc.'s corporate overhead, including finance, HR, legal, and executive teams, and support operations from Tampa and other offices. As a fixed cost base, these expenses do not move much with sales, so they matter for operating leverage and margin control.
- Tampa and office overhead
- Finance, HR, legal, executive
- Fixed cost base
Regulatory and intellectual property
Pacira BioSciences, Inc. must keep paying for FDA compliance, safety monitoring, and patent defense to protect Exparel and other branded products. In 2024, Pacira BioSciences, Inc. reported net sales of $718.2 million, so even small patent lapses or safety issues could hit cash flow hard.
These costs are high, but they defend exclusivity and support premium pricing, which is central to the model.
- Compliance and safety work are ongoing costs.
- Patent protection shields branded revenue.
- Exclusivity helps preserve pricing power.
Pacira’s Cost Base Is Heavy, But It Protects Key Products
Pacira BioSciences, Inc.'s cost base is led by R&D and clinical evidence work, about $47 million in fiscal 2025, plus high COGS for sterile injectable manufacturing, field sales, and regulatory compliance. These costs protect EXPAREL and iovera access, but they also pressure margins when volume or pricing weakens.
| Cost item | 2025 data |
|---|---|
| R&D and clinical studies | About $47 million |
| Net product sales | $718.2 million in 2024 |
| Main cost drivers | COGS, sales force, compliance |
Revenue Streams
EXPAREL net sales
EXPAREL net sales are Pacira BioSciences, Inc.'s main revenue stream, driven by U.S. commercialization of its flagship liposomal bupivacaine pain therapy. In Pacira BioSciences, Inc.'s latest reported year, EXPAREL remained the core branded product and the key cash generator for the business.
ZILRETTA net sales
ZILRETTA is Pacira BioSciences, Inc.'s extended-release knee osteoarthritis injection and one of its two marketed prescription drugs, alongside EXPAREL. Its net sales give Pacira BioSciences, Inc. a second pharmaceutical revenue stream and broaden the pain portfolio beyond surgical use.
iovera system sales
Pacira BioSciences, Inc. earns Revenue Streams from iovera system sales through the U.S. commercialization of its handheld cryoanalgesia device, which delivers targeted cold therapy for pain relief. This line extends Pacira BioSciences, Inc. beyond injectables into non-opioid pain devices, supporting a broader pain-management portfolio.
iovera consumables sales
iovera consumables sales create recurring revenue because each cryoanalgesia procedure needs single-use components and accessories, so Pacira BioSciences, Inc. can earn again as the installed base is used more often. This is a classic procedure-based medtech model: more procedures drive more consumable pull-through.
Pacira BioSciences, Inc. reported 2025 revenue of $570 million, and consumables tied to iovera help turn device adoption into repeat sales.
- Single-use items drive repeat revenue
- Usage rises with procedure volume
- Installed base supports pull-through
Licensing and collaboration income
Pacira BioSciences, Inc. can also earn licensing and collaboration income from technology and partnership deals, including agreements tied to its MVL platform. In 2025, this stream stayed secondary to product sales, but it can still add non-dilutive cash and widen Pacira BioSciences, Inc.'s revenue mix.
- Licensing fees from MVL
- Partner milestone payments
- Supports product revenue
Pacira’s Revenue Is Still Powered by EXPAREL and Growing Add-Ons
Pacira BioSciences, Inc. Revenue Streams are led by EXPAREL, with ZILRETTA and iovera adding product diversity. In 2025, Pacira BioSciences, Inc. reported $570 million revenue, showing a model still anchored in branded pain therapies and supported by recurring consumables and secondary partnership income.
| Stream | 2025 |
|---|---|
| Total revenue | $570 million |
| Main driver | EXPAREL |
| Recurring add-on | iovera consumables |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.